Advertisement
Canada markets open in 2 hours 59 minutes
  • S&P/TSX

    24,471.17
    +168.87 (+0.69%)
     
  • S&P 500

    5,859.85
    +44.82 (+0.77%)
     
  • DOW

    43,065.22
    +201.36 (+0.47%)
     
  • CAD/USD

    0.7243
    -0.0006 (-0.08%)
     
  • CRUDE OIL

    70.34
    -3.49 (-4.73%)
     
  • Bitcoin CAD

    90,701.04
    +1,226.03 (+1.37%)
     
  • XRP CAD

    0.75
    +0.01 (+0.76%)
     
  • GOLD FUTURES

    2,671.70
    +6.10 (+0.23%)
     
  • RUSSELL 2000

    2,248.64
    +14.23 (+0.64%)
     
  • 10-Yr Bond

    4.0980
    +0.0250 (+0.61%)
     
  • NASDAQ futures

    20,582.75
    -36.50 (-0.18%)
     
  • VOLATILITY

    19.78
    +0.08 (+0.41%)
     
  • FTSE

    8,252.10
    -40.56 (-0.49%)
     
  • NIKKEI 225

    39,910.55
    +304.75 (+0.77%)
     
  • CAD/EUR

    0.6635
    -0.0007 (-0.11%)
     

Celldex Therapeutics to Present at Upcoming Investor Conferences

Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.

HAMPTON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:

2024 Cantor Global Healthcare Conference on Tuesday, September 17th at 8:35 a.m. ET

TD Cowen's Chronic Urticaria Summit on Friday, September 20th at 10:00 a.m. ET

Live webcasts of the presentations will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex website. Replays will be available for 90 days following the event.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com